These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25558950)

  • 21. Involvement of palms and soles in patients with autoimmune bullous diseases: a comparative analysis of a diagnostically relevant localization.
    Jałowska M; Spałek M; Bowszyc-Dmochowska M; Gornowicz-Porowska J; Dmochowski M
    Front Immunol; 2023; 14():1227855. PubMed ID: 37885886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
    Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
    JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses.
    Iwata H; Bieber K; Hirose M; Ludwig RJ
    Curr Pharm Des; 2015; 21(18):2422-39. PubMed ID: 25777758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
    Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
    JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases.
    Ohata C; Ishii N; Koga H; Fukuda S; Tateishi C; Tsuruta D; Furumura M; Hashimoto T
    J Am Acad Dermatol; 2015 Jul; 73(1):50-5. PubMed ID: 25896671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and quality of life in pemphigus patients.
    Tee CT; Lee CS; Gunabalasingam P
    Med J Malaysia; 2022 May; 77(3):324-330. PubMed ID: 35638489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal Autoimmune Blistering Disease: A Systematic Review.
    Zhao CY; Chiang YZ; Murrell DF
    Pediatr Dermatol; 2016 Jul; 33(4):367-74. PubMed ID: 27086740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.
    Lee BWH; Tan JCK; Radjenovic M; Coroneo MT; Murrell DF
    Orphanet J Rare Dis; 2018 May; 13(1):83. PubMed ID: 29789014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases.
    Oh DD; Zhao CY; Murrell DF
    J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):595-603. PubMed ID: 26434420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of autoimmune bullous diseases among children in Kuwait.
    Nanda A; Lazarevic V; Rajy JM; Almasry IM; AlSabah H; AlLafi A
    Pediatr Dermatol; 2021 Jan; 38(1):50-57. PubMed ID: 33043506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of an Oral Disease Severity Score (ODSS) tool for use in oral mucous membrane pemphigoid.
    Ormond M; McParland H; Thakrar P; Donaldson ANA; Andiappan M; Cook RJ; Escudier ME; Higham J; Hullah E; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2020 Jul; 183(1):78-85. PubMed ID: 31571192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grading criteria for disease severity by pemphigus disease area index.
    Shimizu T; Takebayashi T; Sato Y; Niizeki H; Aoyama Y; Kitajima Y; Iwatsuki K; Hashimoto T; Yamagami J; Werth VP; Amagai M; Tanikawa A
    J Dermatol; 2014 Nov; 41(11):969-73. PubMed ID: 25346300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review.
    Zeng FAP; Wilson A; Sheriff T; Murrell DF
    JAAD Int; 2022 Dec; 9():33-43. PubMed ID: 36089938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual quality of life in patients with pemphigus: A case-control study.
    Maione V; Bettolini L; Cozzi C; Bighetti S; Tomasi C; Calzavara-Pinton P
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):761-768. PubMed ID: 38071729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune blistering dermatoses as systemic diseases.
    Vassileva S; Drenovska K; Manuelyan K
    Clin Dermatol; 2014; 32(3):364-75. PubMed ID: 24767184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.
    Padniewski JJ; Shaver RL; Schultz B; Pearson DR
    Clin Cosmet Investig Dermatol; 2022; 15():27-42. PubMed ID: 35046687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infection in autoimmune bullous diseases: a retrospective comparative study.
    Lehman JS; Khunger M; Lohse CM
    J Dermatol; 2013 Aug; 40(8):613-9. PubMed ID: 23772962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
    Czernik A; Toosi S; Bystryn JC; Grando SA
    Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Clinical Trials in Pemphigus and Pemphigoid.
    Izumi K; Bieber K; Ludwig RJ
    Front Immunol; 2019; 10():978. PubMed ID: 31130959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.